Production, quality control and clinical applications of radiosynovectomy agents.

"Therapeutic radiopharmaceuticals play a major role in today's nuclear medicine with a positive impact on the diagnosis and treatment of diseases. One area of application is radiation synovectomy (RSV). Previously, RSV agents were often simple colloids. More recently, matrixes labelled wit...

Full description

Bibliographic Details
Call Number:Libro Electrónico
Format: Electronic eBook
Language:Inglés
Published: Vienna : International Atomic Energy Agency, 2021.
Series:IAEA radioisotopes and radiopharmaceuticals reports ; no. 3.
Subjects:
Radiopharmaceuticals.
Synovectomy.
Nuclear medicine.
Radioisotopes > Therapeutic use.
Radiopharmaceuticals
Nuclear Medicine
Radiopharmaceutiques.
Synovectomie.
Médecine nucléaire.
Curiethérapie.
Nuclear medicine
Radioisotopes > Therapeutic use
Synovectomy
Online Access:Texto completo
Table of Contents:
  • Intro
  • 1. INTRODUCTION
  • 1.1. Background
  • 1.2. Objectives
  • 1.3. Scope
  • 1.4. Structure
  • 2. RADIOSYNOVECTOMY IN THE TREATMENT OF SYNOVITIS
  • 2.1. Definition
  • 2.2. History
  • 2.3. Synovial joints
  • 2.4. Synovitis
  • 2.5. Rheumatoid arthritis
  • 2.6. Osteoarthritis
  • 2.7. Haemophilia
  • 2.8. Pigmented villonodular synovitis
  • 3. PATIENT SELECTION FOR RADIOSYNOVECTOMY
  • 3.1. Mechanism of action
  • 3.2. Indications
  • 3.3. Patient preference
  • 3.4. Indication for repeating radiosynovectomy
  • 3.5. Contraindications
  • 3.6. Adverse effects of radiosynovectomy
  • 4. Production of radionuclides required for RADIOSYNOVECTOMY
  • 4.1. Introduction
  • 4.2. Targeting
  • 4.2.1. 198Au
  • 4.2.2. 165Dy
  • 4.2.3. 169Er
  • 4.2.4. 166Ho
  • 4.2.5. 177Lu
  • 4.2.6. 32P
  • 4.2.7. 186Re
  • 4.2.8. 188Re
  • 4.2.9. 153Sm
  • 4.2.10. 117mSn
  • 4.2.11. 90Y
  • 5. Radiopharmaceuticals for RADIOSYNOVECTOMY
  • 5.1. Principle
  • 5.1.1. Radionuclide selection
  • 5.2. Characteristics of radionuclides used in radiosynovectomy
  • 5.3. Particles for radionuclides
  • 5.3.1. Particle selection
  • 5.3.2. Particle size
  • 5.3.3. Common particles used in radiosynovectomy
  • 5.4. Key particles used in radiosynovectomy
  • 5.4.1. Glass
  • 5.4.2. Chitosan
  • 5.4.3. Silicate
  • 5.4.4. Citrate
  • 5.4.5. Polylactic acid
  • 5.4.6. Hydroxyapatite
  • 5.4.7. Hydro- and solvothermal
  • 5.4.8. Solid state reactions
  • 5.4.9. Sol-gel process
  • 5.5. Preparation of radioactive particles
  • 5.5.1. Radiolabelling during particle preparation
  • 5.5.2. Radiolabelled particles after their preparation
  • 5.6. Key radionuclides evaluated for synovectomy
  • 5.6.1. 198Au
  • 5.6.2. 165Dy
  • 5.6.3. 169Er
  • 5.6.4. 166Ho
  • 5.6.5. 177Lu
  • 5.6.6. 32P
  • 5.6.7. 186Re
  • 5.6.8. 188Re
  • 5.6.9. 153Sm
  • 5.6.10. 117mSn
  • 5.6.11. 90Y
  • 6. Method used to prepare particles for RADIOSYNOVECTOMY
  • 6.1. Introduction
  • 6.2. Precipitation
  • 6.3. Emulsion: Evaporation or extraction of solvent
  • 6.4. Sol-gel process
  • 6.5. Spray drying
  • 6.6. Electrospraying
  • 7. Regulatory and Manufacturing Issues
  • 7.1. Radiopharmaceutical manufacturing elements
  • 7.1.1. Personnel
  • 7.1.2. Premises and equipment
  • 7.1.3. Documentation
  • 7.1.4. Training
  • 7.1.5. Quality assurance
  • 7.1.6. Quality control
  • 7.1.7. Responsibilities
  • 7.2. Quality evaluation of radiosynovectomy agents
  • 7.2.1. Quality control of the particle
  • 7.2.2. Quality control of radionuclides
  • 7.2.3. Quality control of radiolabelled particles
  • 7.3. Documentation
  • 7.3.1. General requirements
  • 7.3.2. Preparation procedures
  • 7.3.3. Batch records
  • 7.3.4. Staff training
  • 7.3.5. Validation of training
  • 7.3.6. Retraining
  • 7.3.7. Periodic review of training
  • 8. Standard operating procedure for RADIOSYNOVECTOMY
  • 8.1. Informed consent
  • 8.2. Diagnosis
  • 8.3. Facilities
  • 8.4. Preparation of patients
  • 8.5. Instrumentation
  • 8.6. Utensils

Similar Items